# Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

> **NCT02227875** · PHASE3 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 560 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Mylan's insulin glargine
- **DRUG:** Lantus®

## Key facts

- **NCT ID:** NCT02227875
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2022-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227875, "Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02227875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*